Changing the future of Oncology.
Events
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., July 29, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Nicki Vasquez, SVP Alliance Management/Portfolio Strategy and Operations Interviewed by Elaine Quilici of Pharmaceutical Executive – “Firsthand Views: Latinos in Pharma”
Pharmaceutical Executive Firsthand Views: Latinos in Pharma https://www.pharmexec.com/view/firsthand-views-latinos-in-pharma July 8, 2021 Elaine Quilici Latino executives share their experiences and insights on the community’s contributions to the life sciences...
Bill Newell, CEO Interviewed by Peter Hofland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors...
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June
SOUTH SAN FRANCISCO, Calif., June 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Poster
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian Cancer Download Poster, CLICK HERE
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian CancerDownload Presentation, CLICK HERE
Jefferies Virtual Healthcare Conference 2021 – Presentation
Webcast, Click Here Download Presentation, Click Here
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – STRO-002 – Abstract
To view the abstract on ASCO, click here
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed...
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...